Solid Tumor Targeting CAR-T Development Service by Balancing Glycolysis & Oxidative Phosphorylation

Are you currently challenged by CAR-T cell exhaustion within the immunosuppressive solid tumor microenvironment (TME), limited T-cell persistence, or inadequate memory formation? Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Balancing Glycolysis & Oxidative Phosphorylation is designed to overcome these barriers. Through advanced metabolic engineering and epigenetic modulation techniques, we optimize the cellular energy balance—fine-tuning glycolytic flux while reinforcing oxidative phosphorylation (OXPHOS) capacity. Our integrated approach ensures robust effector function and promotes long-lived memory T cell phenotypes, enabling enhanced persistence and sustained tumoricidal activity even in metabolically hostile tumors.

Introduction

In CAR-T cell therapy, glycolysis serves as the primary bioenergetic source that fuels rapid effector functions, including cytokine production and cytotoxic activity, essential for immediate tumor clearance. Conversely, OXPHOS supports the development and maintenance of memory T cell phenotypes, underpinning long-term persistence and sustained antitumor immunity. Striking a dynamic balance between glycolysis and OXPHOS is therefore critical to simultaneously empower potent tumoricidal activity and ensure durable functional persistence of CAR-T cells, particularly within the metabolically hostile tumor microenvironment.

Fig.1 Metabolic reprogramming in CAR design: glycolysis and oxidative phosphorylation.¹

Solid Tumor Targeting CAR-T Development Service by Balancing Glycolysis & Oxidative Phosphorylation at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Balancing Glycolysis & Oxidative Phosphorylation offers a definitive solution to the challenge of CAR-T cell functional decline in the solid TME. Our service focuses on two critical metabolic states: maintaining high Glycolysis for rapid effector function (killing) and enhancing OXPHOS/FAO for T cell memory imprinting and persistence.

What We Can Offer

We offer a comprehensive suite of advanced technologies for solid tumor CAR-T development, centered on multi-dimensional metabolic reprogramming. Our integrated approach, spanning from precise metabolic phenotyping and genetic engineering to epigenetic modulation and synthetic biology, ensures the generation of metabolically robust, long-lived CAR-T cells capable of overcoming the immunosuppressive tumor microenvironment.

Our Service Process

Required Starting Materials:

• Construct Design: CAR sequence (or target antigen/scaffold) and desired co-stimulatory domain.
• T Cell Source: PBMCs or isolated T cell subsets.
• Tumor Model: Target cell lines, PDX models, or patient TME metabolic profiles (if available).

Key Steps:

Final Deliverables:

• Comprehensive Metabolic Profile Report: Detailed T cell energy maps and pathway flux data.
• Optimized CAR-T Cell Bank: CAR-T cells validated for enhanced persistence and metabolic resilience.
• Full Efficacy & Safety Data Package: Such as in vitro cytotoxicity, cytokine release.

Key Advantages

• Custom Metabolic Phenotyping: We conduct bespoke metabolic assessments of your CAR construct and T cell source to identify specific metabolic bottlenecks and tailor the reprogramming strategy accordingly.
• Targeted Pathway Modulation: We offer efficient upstream and downstream process development for CAR-T engineering, specializing in modulating key metabolic regulators like AMPK, mTOR, and HIF-1α to actively resist exhaustion and promote the memory phenotype.
• Engineered Fuel Accessibility: Our proprietary methods allow us to enhance T cell access to critical nutrients, specifically boosting the glycolytic reserve (via transporters like GLUT1) to ensure the cells can sustain high levels of both killing (Glycolysis) and persistence (OXPHOS).

FAQs

Why Choose Us?

Creative Biolabs pioneers immuno-metabolic CAR-T engineering for solid tumors. We uniquely optimize the glycolysis-OXPHOS balance, enhancing GLUT1-mediated fuel uptake to sustain both potent cytotoxicity and long-lived memory. Our epigenetic strategies lock in this anti-exhaustion phenotype, ensuring persistent function against challenging TMEs. Choose us for durable efficacy rooted in deep metabolic insight.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service in our research has significantly improved the efficiency of our Treg suppression assays. The clear demonstration of metabolic shift from glycolysis to FAO provided by their metabolic report package was crucial for moving our lead compound forward." Mar** **o D***on.

"The CAR-T cells we received showed dramatically lower exhaustion markers PD-1, compared to our internal controls. Their specialized epigenetic analysis confirmed that the memory phenotype was stably imprinted, giving us confidence in the long-term therapeutic potential. We achieved a 2-fold higher T cell proliferation rate in the TME mimetic assays." Kat***ya P***ov.

"We chose Creative Biolabs after struggling with poor persistence in our Phase I candidates. Their GLUT1 optimization strategy solved the glucose bottleneck, leading to a demonstrable improvement in tumor regression in our animal models, which they clearly showed was linked to enhanced mitochondrial function (higher OXPHOS reserve) compared to previous constructs." Joh***es B***er.

How to Contact Us?

To discuss your specific solid tumor target, review our detailed case studies, or initiate a project utilizing our CAR-T Metabolic Engineering Service, please reach out to our expert team.

Reference

1. Rial Saborido, Judit et al. "Role of CAR T Cell Metabolism for Therapeutic Efficacy." Cancers vol. 14,21 5442. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers14215442.